UROLOGIX INC (OTCMKTS:ULGX) Sellers Decreased Their Shorts By 7.45% As Of Jun 27, 2018

June 27, 2018 - By Tracy Fowler

Big Money Sentiment decreased to 0 in 2018 Q1. It has change of Infinity, from 2017Q4’s Infinity. The ratio turned negative due to Urologix, Inc. positioning: 0 sold and 0 reduced. 0 funds bought holdings and 0 increased holdings. Investors holded 60,521 in 2017Q4 but now own 60,521 shares or 0.00% without change.
Mairs & Power Incorporated invested 0% in Urologix, Inc. (OTCMKTS:ULGX). Gemmer Asset Mngmt Ltd Liability Co holds 40,521 shs or 0% of its capital.

Change of 7.45% for UROLOGIX INC (OTCMKTS:ULGX)’s short interest was reported. It was published in June by FINRA the 38,500 short interest on ULGX. The down change of 7.45% from 41,600 shares was reported. UROLOGIX INC (OTCMKTS:ULGX) has 286,700 shares average volume. It’ll cost 0 days for ULGX to restore its previous position.

ULGX is reaching $0.07311 during the last trading session, after increased 4.44%.Currently Urologix, Inc. is after 0.00% change in last June 27, 2017. ULGX has 134,846 shares volume. ULGX underperformed the S&P500 by 12.57%.

Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia in the United States.The firm is worth $1.56 million. The firm offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort.Last it reported negative earnings. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: